PHILADELPHIA, May 5, 2011 /PRNewswire/ — Echo Therapeutics,
Inc. (OTCBB: ECTE), a company developing the Symphony™ tCGM
System as a non-invasive, wireless, transdermal continuous glucose
monitoring (tCGM) system and the Prelude™ SkinPrep System for
transdermal drug delivery, today announced the relocation of its
corporate headquarters from Franklin, MA to Philadelphia, PA.
The new office is located in the heart of Philadelphia’s Center
City Business District at 8 Penn Center. Echo will continue
to maintain and grow its Franklin office as its key operations hub
where its engineering and product personnel are located.
“Since Echo Therapeutics’ inception, the company has maintained
its headquarters in Franklin where we have enjoyed a rewarding
history of growth and success,” stated Patrick Mooney, M.D., Echo’s
Chairman and CEO. “The new headquarters responds directly to
Echo’s growing and evolving business and will accommodate both
recent team expansion and additional hires planned for 2011 and
beyond.”
Echo operates at the following locations:
8 Penn Center, 1628 JFK Boulevard, Suite 300, Philadelphia, PA
19103 (Headquarters)
10 Forge Parkway, Franklin, MA 02038
About Echo TherapeuticsEcho Therapeutics is developing the
Symphony tCGM System as a non-invasive, wireless, transdermal
continuous glucose monitoring system for patients with diabetes and
for use in hospital critical care units. Echo is also
developing its needle-free Prelude SkinPrep System as a platform
technology for enhanced skin permeation for delivery of topical
pharmaceuticals. For More Information:Patrick T. Mooney,
M.D.
Media: Richard SternChairman and Chief Executive
Officer
Stern &Co.(215) 717-4100
(212) 888-0044Connect With Us:- Visit our website at www.echotx.com
– Follow us on Twitter at www.twitter.com/echotx<
‘/>”/>
SOURCE
